Literature DB >> 10721057

Neuroprotective effects of kynurenine-3-hydroxylase inhibitors in models of brain ischemia.

F Moroni1, A Cozzi, F Peruginelli, R Carpenedo, D E Pellegrini-Giampietro.   

Abstract

The neuroprotective effects of two kynurenine hydroxylase inhibitors, (m-nitrobenzoyl)-alanine (mNBA) and 3,4-dimethoxy-[-N-4-(nitrophenyl)thiazol-2yl]-benzenesulfona mide (Ro 61-8048), were studied in vitro and in vivo. In organotypic hippocampal slice cultures deprived of oxygen and glucose, these inhibitors significantly reduced neuronal damage. In gerbils subjected to bilateral carotid occlusion for 5 min, the administration of mNBA (400 mg/kg i.p., 3 times) or Ro 61-8048 (40 mg/kg i.p., 3 times) dramatically decreased the percentage of damaged pyramidal neurones in the hippocampal CA1 region. Finally, in rats with permanent occlusion of the middle cerebral artery, mNBA (200-400 mg/kg i.p.) and Ro 61-8048 (40 mg/kg i.p.) administration reduced the infarct volume. Our results demonstrate that ischemic neuronal damage may be significantly decreased by inhibiting kynurenine hydroxylase.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10721057     DOI: 10.1007/978-1-4615-4709-9_26

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  8 in total

1.  Kynurenine 3-monooxygenase inhibition in blood ameliorates neurodegeneration.

Authors:  Daniel Zwilling; Shao-Yi Huang; Korrapati V Sathyasaikumar; Francesca M Notarangelo; Paolo Guidetti; Hui-Qiu Wu; Jason Lee; Jennifer Truong; Yaisa Andrews-Zwilling; Eric W Hsieh; Jamie Y Louie; Tiffany Wu; Kimberly Scearce-Levie; Christina Patrick; Anthony Adame; Flaviano Giorgini; Saliha Moussaoui; Grit Laue; Arash Rassoulpour; Gunnar Flik; Yadong Huang; Joseph M Muchowski; Eliezer Masliah; Robert Schwarcz; Paul J Muchowski
Journal:  Cell       Date:  2011-06-10       Impact factor: 41.582

2.  A genomic screen in yeast implicates kynurenine 3-monooxygenase as a therapeutic target for Huntington disease.

Authors:  Flaviano Giorgini; Paolo Guidetti; QuangVu Nguyen; Simone C Bennett; Paul J Muchowski
Journal:  Nat Genet       Date:  2005-04-03       Impact factor: 38.330

Review 3.  Involvement of quinolinic acid in AIDS dementia complex.

Authors:  Gilles J Guillemin; Stephen J Kerr; Bruce J Brew
Journal:  Neurotox Res       Date:  2005       Impact factor: 3.911

Review 4.  The involvement of astrocytes and kynurenine pathway in Alzheimer's disease.

Authors:  Ka Ka Ting; Bruce Brew; Gilles Guillemin
Journal:  Neurotox Res       Date:  2007-12       Impact factor: 3.911

5.  On the relationship between the two branches of the kynurenine pathway in the rat brain in vivo.

Authors:  Laura Amori; Paolo Guidetti; Roberto Pellicciari; Yasushi Kajii; Robert Schwarcz
Journal:  J Neurochem       Date:  2009-02-06       Impact factor: 5.372

6.  Cellular Localization of Kynurenine 3-Monooxygenase in the Brain: Challenging the Dogma.

Authors:  Korrapati V Sathyasaikumar; Verónica Pérez de la Cruz; Benjamín Pineda; Gustavo Ignacio Vázquez Cervantes; Daniela Ramírez Ortega; David W Donley; Paul L Severson; Brian L West; Flaviano Giorgini; Jonathan H Fox; Robert Schwarcz
Journal:  Antioxidants (Basel)       Date:  2022-02-04

Review 7.  Kynurenines with neuroactive and redox properties: relevance to aging and brain diseases.

Authors:  Jazmin Reyes Ocampo; Rafael Lugo Huitrón; Dinora González-Esquivel; Perla Ugalde-Muñiz; Anabel Jiménez-Anguiano; Benjamín Pineda; José Pedraza-Chaverri; Camilo Ríos; Verónica Pérez de la Cruz
Journal:  Oxid Med Cell Longev       Date:  2014-02-17       Impact factor: 6.543

Review 8.  Role of Kynurenine Pathway in Oxidative Stress during Neurodegenerative Disorders.

Authors:  Adrian Mor; Anna Tankiewicz-Kwedlo; Anna Krupa; Dariusz Pawlak
Journal:  Cells       Date:  2021-06-26       Impact factor: 6.600

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.